Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel

  CHF 27 million investment significantly bolsters Boehringer’s ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.  Boehringer Ingelheim strengthens footprint in Swiss biotech innovation hub.  Basel, Switzerland, Thursday, 03.04.2025 (Korea Bizwire) –Today NBE Therapeutics (NBE) a wholly owned subsidiary of  Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel. This milestone reinforces its commitment to innovation in oncology and strengthens its footprint [...]